What does Grove Biopharma do?
Grove Biopharma is a biotechnology company that develops its proprietary Bionic Biologics platform. This platform integrates biologic and synthetic design principles to create novel therapies targeting intracellular protein-protein interactions, opening new avenues for therapeutic intervention.
How much did they raise?
The company raised $30M in a Series A round led by DCVC Bio, with participation from Eli Lilly and Company, InVivium Capital, Walder Ventures, Gradiant Corporation, Mansueto Investments, and Portal Innovations.
What are their plans for the money?
The funds will be used to further advance the Bionic Biologics platform and drive the company’s lead oncology programs toward clinical trials, potentially ushering in innovative treatments for previously intractable disease targets.
What have they achieved so far?
Grove Biopharma, a spinout from Northwestern University, has already made progress by assembling a multidisciplinary team of experts in chemistry, biology, materials science, and entrepreneurship, which positions it well to tackle challenging targets in the biotech space.
